OptiBrand Rx

In metastatic castration-resistant prostate cancer, every additional treatment option matters.

JEVTANA® (cabazitaxel) was developed to support patients whose disease has progressed after prior docetaxel treatment, helping address one of the most complex stages of prostate cancer care. Its approval marked an important advancement for patients facing limited therapeutic options.

OptiBrand RX is proud to support work connected to therapies that continue pushing oncology care forward and expanding possibilities for patients and providers navigating difficult treatment journeys.

Learn more: https://www.jevtana.com/

Today we highlight Yuviwel® (navepegritide), a February 2026 FDA-approved therapy developed to support growth in children living with achondroplasia, the most common form of dwarfism.

As the first once-weekly CNP analog approved for this condition, Yuviwel represents an important advancement in rare pediatric disease care, helping reduce treatment burden while targeting the underlying biology that affects bone growth.

Why this matters:

• Achondroplasia is a rare genetic condition associated with lifelong skeletal and developmental challenges.
• Treatment adherence can be difficult in chronic pediatric conditions requiring frequent injections.
• Once-weekly administration may help reduce burden while supporting more consistent care routines.

OptiBrand is proud to spotlight innovations that bring new possibilities to underserved patient communities and help improve long-term treatment experiences for children and families.

Learn more: https://yuviwel.com/

Today we highlight Zoladex® (goserelin), a hormone therapy that plays a critical role in the treatment of hormone-sensitive cancers and gynecologic conditions.

Zoladex is a GnRH agonist that works by suppressing the production of key hormones like testosterone and estrogen, which are hormones that can fuel the growth of certain cancers. By reducing these levels, it helps slow disease progression at its source.

Used across indications including prostate cancer, breast cancer, and endometriosis, Zoladex represents a well-established approach in endocrine therapy, where targeting hormonal pathways can meaningfully impact outcomes.

In complex treatment landscapes, therapies like Zoladex demonstrate how understanding and intervening in underlying biology can reshape care strategies.

OptiBrand recognizes the importance of innovations that address disease at a foundational level, especially when they expand options for patients navigating long-term, hormone-driven conditions.

Learn more: https://www.zoladex.com/

Today we highlight Nemluvio®, a targeted monoclonal antibody designed to address chronic pruritic inflammatory skin diseases, including atopic dermatitis and prurigo nodularis.

Nemluvio works by inhibiting IL-31 signaling, a key neuroimmune pathway strongly associated with itch, inflammation, and skin barrier dysfunction. By targeting the underlying biology of the itch-scratch cycle, Nemluvio helps reduce symptoms that significantly impact quality of life.

As dermatology continues to evolve toward more precise immune modulation, therapies like Nemluvio highlight the importance of targeting specific cytokine pathways to address complex chronic inflammatory conditions.

OptiBrand is proud to spotlight innovations that translate deeper immunologic understanding into meaningful symptom relief for patients living with persistent skin disease.

Learn more: https://www.nemluvio.com/